Inventor
WOODDELL CHRISTINE I
US13 patents
⚠️ This page may combine multiple inventors who share the name “WOODDELL CHRISTINE I”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ARROWHEAD PHARMACEUTICALS INC
11 patentsUS10450565B2Oct 22, 2019
Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
ARROWHEAD PHARMACEUTICALS INC15 citations94
US10130651B2Nov 20, 2018
RNAi Therapy for Hepatitis B Virus Infection
ARROWHEAD PHARMACEUTICALS INC22 citations94
US11203756B2Dec 21, 2021
Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
ARROWHEAD PHARMACEUTICALS INC5 citations84
US12188017B2Jan 7, 2025
Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin
ARROWHEAD PHARMACEUTICALS INC1 citations73
US11884920B2Jan 30, 2024
Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
ARROWHEAD PHARMACEUTICALS INC2 citations73
US10806750B2Oct 20, 2020
RNAi therapy for hepatitis B virus infection
ARROWHEAD PHARMACEUTICALS INC3 citations73
US11590156B2Feb 28, 2023
RNAi agents for hepatitis B virus infection
ARROWHEAD PHARMACEUTICALS INC2 citations72
US11517584B2Dec 6, 2022
RNAi agents for Hepatitis B virus infection
ARROWHEAD PHARMACEUTICALS INC2 citations72
US11384355B2Jul 12, 2022
Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin
ARROWHEAD PHARMACEUTICALS INC3 citations72
US11534453B2Dec 27, 2022
RNAi therapy for hepatitis B virus infection
ARROWHEAD PHARMACEUTICALS INC0 citations62
US12582668B2Mar 24, 2026
Methods for the treatment of alpha-1 antitrypsin deficiency (AATD)
ARROWHEAD PHARMACEUTICALS INC0 citations45